To develop a novel drug loading strategy for exosomes with broad clinical applications

开发具有广泛临床应用的新型外泌体载药策略

• 批准号: 10044875
• 金额: $ 3.46万
• 依托单位: THERAPORT LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10044875
• 关键词: develop; novel; drug; loading; strategy

Our project aims to improve drug loading efficiency into exosomes - small extracellular vesicles which are secreted by our cells and used to traffic molecular cargo from one cell to another. Exosomes have emerged as an exciting drug delivery vehicle and several clinical trials have demonstrated both the safety and efficacy of exosome formulations. As a targeted drug delivery strategy they can package small molecule, peptide and nucleic acid based drugs - enhancing drug stability in the body and cell uptake as well as having the potential for engineered targeting.Our technology will improve exosome-based treatments for a broad spectrum of diseases through increasing the scalability and reducing the heterogeneity in development of the therapeutic. We aim to do this through generation of a platform of proteins we call 'loading factors'. The project will involve proof of concept experiments that demonstrate the efficacy of the loading factors for this purpose.

我们的项目旨在提高外泌体的药物装载效率-外泌体是由我们的细胞分泌的小细胞外囊泡，用于将分子货物从一个细胞运输到另一个细胞。外泌体已经成为一种令人兴奋的药物递送载体，并且一些临床试验已经证明了外泌体制剂的安全性和有效性。作为一种靶向药物递送策略，它们可以包装小分子、肽和核酸药物，增强药物在体内的稳定性和细胞摄取，并具有工程靶向的潜力。我们的技术将通过增加可扩展性和减少治疗开发的异质性来改善基于外泌体的治疗，用于广泛的疾病。我们的目标是通过生成一种我们称之为“加载因子”的蛋白质平台来实现这一目标。该项目将涉及概念验证实验，以证明负荷系数在这方面的功效。